NASDAQ:ICPT Intercept Pharmaceuticals (ICPT) News Today $18.54 -0.03 (-0.16%) (As of 09/29/2023 08:53 PM ET) Add Compare Share Share Today's Range$18.51▼$18.6150-Day Range$9.99▼$18.7152-Week Range$8.82▼$21.86Volume3.89 million shsAverage Volume1.27 million shsMarket Capitalization$774.60 millionP/E Ratio2.90Dividend YieldN/APrice Target$23.18 HeadlinesProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineIntercept Pharmaceuticals (NASDAQ:ICPT) Given "Hold" Rating at Canaccord Genuity Groupamericanbankingnews.com - September 30 at 5:15 AMHC Wainwright Downgrades Intercept Pharmaceuticals (NASDAQ:ICPT) to Neutralamericanbankingnews.com - September 29 at 4:41 AMB. Riley Comments on Intercept Pharmaceuticals, Inc.'s FY2025 Earnings (NASDAQ:ICPT)americanbankingnews.com - September 29 at 2:21 AMIntercept Pharma unlikely to see rival offers, other roadblocks, analysts saymsn.com - September 28 at 10:48 PMCanaccord Genuity Downgrades Intercept Pharmaceuticals (ICPT)msn.com - September 28 at 10:48 PMIntercept Pharmaceuticals (NASDAQ:ICPT) PT Raised to $19.00 at Royal Bank of Canadaamericanbankingnews.com - September 28 at 4:23 AMIntercept Pharmaceuticals (NASDAQ:ICPT) Sees Strong Trading Volume After Analyst Upgradeamericanbankingnews.com - September 28 at 1:32 AMRoyal Bank of Canada Increases Intercept Pharmaceuticals (NASDAQ:ICPT) Price Target to $19.00marketbeat.com - September 27 at 9:40 AMIntercept Pharma Acquisition by Alfasigma: A Strategic Move and Fair Value Assessmentmarkets.businessinsider.com - September 27 at 5:01 AMIntercept Pharmaceuticals stock soars on Alfasigma acquisition dealproactiveinvestors.com - September 27 at 5:01 AMIntercept Pharmaceuticals (NASDAQ:ICPT) Downgraded by B. Riley to "Neutral"americanbankingnews.com - September 27 at 3:52 AMCanaccord cuts Intercept to hold, calls Alfasigma deal "best possible outcome"msn.com - September 26 at 9:08 PMShareholder Alert: Ademi LLP investigates whether Intercept Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Alfasigmabenzinga.com - September 26 at 4:07 PMIntercept Pharmaceuticals: Alfasigma Pays Premium For M&A Deal That Suits All Partiesseekingalpha.com - September 26 at 3:35 PMWhy Is Intercept Pharmaceuticals (ICPT) Stock Up 75% Today?investorplace.com - September 26 at 3:10 PMIntercept Pharma Shares Surge Toward Alfasigma Acquisition Pricemarketwatch.com - September 26 at 11:07 AMIntercept Pharmaceuticals’ stock set to soar after Alfasigma buyout deal for an 82% premiummsn.com - September 26 at 11:07 AMItaly's Alfasigma to buy drugmaker Intercept for nearly $800 mlnreuters.com - September 26 at 11:07 AMAlfasigma To Acquire Intercept Pharma Fo $19 Per Share In Cashmarkets.businessinsider.com - September 26 at 11:07 AMWhy Is Rare Liver Disease Focused Intercept Pharmaceuticals Stock Trading Higher Today?markets.businessinsider.com - September 26 at 11:07 AMAlfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver Diseasesfinance.yahoo.com - September 26 at 11:07 AMUPDATE 2-Italy's Alfasigma to buy US liver disease drugmaker Intercept for nearly $800 mlnfinance.yahoo.com - September 26 at 11:07 AMmarketbeat.com - September 26 at 7:59 AMZacks Research Weighs in on Intercept Pharmaceuticals, Inc.'s FY2024 Earnings (NASDAQ:ICPT)americanbankingnews.com - September 22 at 2:20 AMFY2025 EPS Estimates for Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Lifted by Zacks Researchmarketbeat.com - September 20 at 6:38 AMIntercept Pharma (ICPT) Receives a Hold from RBC Capitalmarkets.businessinsider.com - September 9 at 12:09 AMWhy CymaBay Therapeutics Stock Is Jumping Todayfinance.yahoo.com - September 8 at 2:08 PMWhy Is Fate Therapeutics (FATE) Down 23.5% Since Last Earnings Report?finance.yahoo.com - September 7 at 3:39 PMCredit Suisse AG Has $1.71 Million Stock Holdings in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)marketbeat.com - September 6 at 4:24 AMExodusPoint Capital Management LP Has $1.04 Million Stock Holdings in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)marketbeat.com - September 5 at 5:27 AMWhy Is Intercept (ICPT) Up 0.6% Since Last Earnings Report?finance.yahoo.com - September 1 at 5:23 PMLeerink Partnrs Equities Analysts Lift Earnings Estimates for Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)marketbeat.com - August 28 at 2:18 AMIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Shares Acquired by Pictet Asset Management SAmarketbeat.com - August 23 at 6:10 AMIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Shares Bought by Mirae Asset Global Investments Co. Ltd.marketbeat.com - August 22 at 4:21 AMQ3 2023 Earnings Forecast for Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Issued By Zacks Researchmarketbeat.com - August 21 at 1:52 AMZacks Research Weighs in on Intercept Pharmaceuticals, Inc.'s Q2 2024 Earnings (NASDAQ:ICPT)marketbeat.com - August 18 at 8:18 AMIntercept Pharmaceuticals (NASDAQ:ICPT) Downgraded to Hold at StockNews.commarketbeat.com - August 11 at 1:10 AMB. Riley Weighs in on Intercept Pharmaceuticals, Inc.'s FY2025 Earnings (NASDAQ:ICPT)marketbeat.com - August 7 at 8:28 AMCanaccord Genuity Maintains Intercept Pharmaceuticals (ICPT) Buy Recommendationmsn.com - August 4 at 2:38 AMIntercept: Narrowed Market, Concentrated Strategy (Rating Upgrade)seekingalpha.com - August 3 at 6:45 PMIntercept Pharmaceuticals, Inc.: Intercept Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Updatesfinanznachrichten.de - August 2 at 1:17 PMIntercept Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Updatesfinance.yahoo.com - August 2 at 1:17 PMIntercept (ICPT) Q2 Earnings Top Estimates, Revenues Up Y/Yfinance.yahoo.com - August 2 at 1:16 PMIntercept Pharmaceuticals, Inc. 2023 Q2 - Results - Earnings Call Presentationseekingalpha.com - August 2 at 9:36 AMIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Receives Average Recommendation of "Moderate Buy" from Brokeragesmarketbeat.com - August 2 at 2:44 AMArizona State Retirement System Makes New Investment in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)marketbeat.com - August 1 at 6:15 AMVirtu Financial LLC Buys Shares of 17,609 Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)marketbeat.com - July 27 at 5:24 AMIntercept to Announce Second Quarter 2023 Financial Results on August 2, 2023finance.yahoo.com - July 26 at 8:11 PMIntercept Pharmaceuticals (ICPT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?finance.yahoo.com - July 26 at 8:11 PMHC Wainwright & Co. Upgrades Intercept Pharmaceuticals (ICPT)msn.com - July 13 at 3:42 PM Get Intercept Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ICPT and its competitors with MarketBeat's FREE daily newsletter. Email Address ICPT Media Mentions By Week ICPT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ICPT News Sentiment▼0.220.69▲Average Medical News Sentiment ICPT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ICPT Articles This Week▼324▲ICPT Articles Average Week Get Intercept Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ICPT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: LXRX News Today VNDA News Today VSTM News Today RIGL News Today MACK News Today EBS News Today XOMA News Today INVA News Today LGND News Today MNKD News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat Originals This page (NASDAQ:ICPT) was last updated on 10/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intercept Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.